Extrathymic tumors in patients with myasthenia gravis: a 35-year retrospective study.
OBJECTIVE
Autoimmune diseases are frequently associated with malignant tumor. In addition, prolonged immunosuppression may favor the development of malignancy. While the coincidence of myasthenia gravis and extrathymic tumor has been reported, the risk and features of these tumors are not well understood.


RESULTS
We treated 305 patients with myasthenia gravis from 1968-2003, including 48 thymoma cases. Two hundred twenty-nine patients had undergone thymectomy and 76 had not. We examined cancer risk, tumor characteristics, and associations to medications. We encountered 9 cases of extrathymic tumor. Cancer risk in the thymoma cases was 6.3% and 2.3% in the nonthymoma cases, a statistically insignificant difference. Azathioprine was administered to only 14 in this series of patients; however, 2 patients developed cancer.


CONCLUSIONS
Cancer risk in patients with myasthenia gravis is 2.6%, similar to that of the general population in Japan. We neurologists need to be aware that prolonged immunosuppression may favor the development of malignancy.
Wakata
Nobuo
N
Department of Neurology, Toho University School of Medicine, Oohashi Hospital, Tokyo, Japan. waka@oha.toho-u.ac.jp
Sugimoto
Hideki
H
Nomoto
Nobuatsu
N
Konno
Singo
S
Nakazora
Hiroshi
H
Nemoto
Hiroshi
H
Karihara
Teruyuki
T
D000328:Adult; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications* / Q000628:therapy; D009369:Neoplasms / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D018570:Risk Assessment; D013950:Thymus Gland / Q000473:pathology; D016896:Treatment Outcome
D007166:Immunosuppressive Agents